HPV monitoring after chemoradiotherapy for cervical cancer
Official title: Implementation of HPV Testing in Patients After Radiotherapy for Cervical Cancer
Run by General University Hospital, Prague · NCT07493928 · Data updated 2026-11-12
This project will test whether HPV detected on cervical swabs and in blood can find cancer recurrence in people with stage IB–IVA cervical cancer after curative chemoradiotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 120 (estimated) |
| Sponsor | General University Hospital, Prague Academic / other |
| Locations | 1 site (Prague) |
| Status | Recruiting |
| Started | February 1, 2026 |
| Main results expected | February 1, 2028 |
| Study ends | February 1, 2030 |
| Registry record updated | March 25, 2026 |
| Trial ID | NCT07493928 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with FIGO stage IB–IVA cervical cancer planned for primary curative chemoradiotherapy, who have not had prior pelvic radiotherapy or hysterectomy and do not have significant immunodeficiency, are ideal candidates.
✕Probably not a fit
Patients with FIGO IA or IVB disease, prior pelvic radiotherapy or hysterectomy, significant immunodeficiency (such as HIV), or HPV-negative tumors are unlikely to benefit from this HPV-based monitoring approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
HART is a prospective multicenter observational study enrolling 120 adults with FIGO stage IB–IVA cervical cancer treated with curative-intent chemoradiotherapy. HPV detection will use PCR-based testing of cervical swabs and analysis of circulating HPV tumor DNA (ctDNA) in blood collected before treatment and at 3, 12, and 24 months after completion of therapy. The primary goal is to determine the sensitivity of these molecular methods for identifying disease recurrence over a two-year follow-up period. Patients with prior pelvic radiotherapy, prior hysterectomy, HIV, or FIGO IA/IVB disease are excluded, and the study is conducted at the General Faculty Hospital in Prague.
Why it matters
Potential benefit: If successful, HPV-based swab and blood monitoring could detect recurrences earlier than current surveillance and allow faster clinical intervention.
How similar studies have gone: Smaller studies and pilot data suggest HPV ctDNA and swab testing can signal recurrence earlier than imaging or exam, but larger prospective validation is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient indicated for primary RT for cervical cancer * FIGO stage IB - IVA * Signed informed consent * Age ≥ 18 years * Administration of RT with curative intent Exclusion Criteria: * Clinical stage FIGO IA * Clinical stage FIGO IVB * History of radiotherapy in the pelvis * Hysterectomy performed before the start of radiotherapy (adjuvant RT) * History of HPV-associated malignancy in personal history * HIV or other significant immunodeficiency
Where it's running
-
General Faculty Hospital in Prague
Prague, Czechia Recruiting
Study contacts
- Study coordinator: Lukas Dostalek, MD, PhD
- Email: lukas.dostalek@vfn.cz
- Phone: +420224967451
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Analysis of outcomes and side effects in patients receiving radiation therapy
This study looks at the results and side effects of radiation therapy in patients at Winterthur Cantonal Hospital to see how treatment can be improved for future patients.
-
Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread
This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.
-
Tributyrin as a dietary supplement to help prevent radiation-induced rectal injury during rectal cancer chemoradiation
This study tests whether adding tributyrin to standard chemoradiotherapy helps prevent acute radiation-induced rectal injury in people with locally advanced rectal cancer.
-
Non-invasive test to predict early heart rejection in pediatric transplant patients
This study tests non-invasive heart tests like cardiac MRI and blood markers to see if they can detect rejection in kids after heart transplant, potentially reducing the need for invasive biopsies.
-
Can people collect their own vaginal sample for HPV testing as well as clinician collection for comparison?
This study tests whether individuals can correctly use a self-collection device to gather a vaginal sample for high-risk HPV screening and whether the self-collected sample agrees with clinician-collected samples.
-
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC
This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.